Abstract 103P
Background
Texture analysis is used to assess the homogeneous or nonhomogenous information of the selected regions, and provides many quantitative and semiquantitative parameters that are able to closely reflect the characteristics of cancer lesions. This study was designed to estimate the clinical significance of the contrast-enhanced computed tomograpgy (CT) textural features for prediction of survival in colorectal cancer (CRC) patients receiving targeted therapy (bevacizumab and cetuximab).
Methods
The LifeX software was used to extract the textural parameters of the tumor lesions in the contrast-enhanced CT. Univariate and multivariate analyses using the Cox proportional hazards model were performed to assess the prognostic value of textural parameters.
Results
Eighty CRC patients receiving targeted therapy (bevacizumab 42; cetuximab 38) were included. In the multivariate analysis, 8 textural parameters were revealed to be independent predictors (p < 0.05) of progression-free survival (PFS) and overall survival (OS), including Skewness, Kurtosis, Homogeneity, Energy and Entropy of Gray-level co-occurrence matrix (GLCM), Long-run emphasis (LRE), Long-run high gray-level emphasis (LRHGE), and Contrast. Furthermore, Sphericity, Compacity, Long-run low gray-level emphasis (LRLGE), Low gray-level zone emphasis (LGZE) and Short-zone low gray-level emphasis (SZLGE) were show to be significantly associated with PFS, while Entropy-Histogram and Energy-Histogram, Dissimilarty, Short-run emphasis (SRE), Short-run low gray-level emphasis (SRLGE), Run percentage (RP), Long-zone emphasis (LZE), Long-zone low gray-level emphasis (LZLGE) and Long-zone high gray-level emphasis (LZHGE) were significantly associated with OS.
Conclusions
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract